Clinical Trial Update: A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for belzutifan (PT2977, MK-6482) in Von Hippel-Lindau disease-associated renal cell carcinoma; the study (NCT03401788) is active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• Welireg (belzutifan)

Snippet

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING